No Data
Earnings Preview: VTGN to Report Financial Results Post-market on November 07
$VistaGen Therapeutics(VTGN.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $VistaGen Therapeutics(VTGN.US)$ to post revenue of USD3
Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Maxim Group analyst Jason McCarthy maintains $VistaGen Therapeutics(VTGN.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.